Loading...
Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy
Liao, K. Wong, D. C. Gomes, F. Faivre-Finn, C. Moliner, L. Sperrin, M. Yorke, J. van der Veer, S. N.
Liao, K.
Wong, D. C.
Gomes, F.
Faivre-Finn, C.
Moliner, L.
Sperrin, M.
Yorke, J.
van der Veer, S. N.
Abstract
OBJECTIVE: Investigate whether routinely collected electronic patient-reported outcome measures (ePROMs) add prognostic value to clinical and tumour characteristics for adults with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy. METHODS AND ANALYSIS: We retrospectively analysed data from adults with advanced NSCLC commencing immunotherapy between April 2019 and June 2022. Prognostic factors were ePROMs on quality of life (EuroQoL five-dimension five-level (EQ-5D-5L); EuroQoL Visual Analogue Scale (EQ-VAS)) and symptoms (patient-reported version of the Common Terminology Criteria for Adverse Events v5.0) completed at baseline and the first follow-up. We performed Cox proportional hazard regression for overall survival and time-to-progression as outcomes, and logistic regression for the onset of severe treatment toxicities (grade ≥3). RESULTS: We included 379 patients; 161 (42.5%) completed ePROMs at baseline. Median overall survival and time-to-progression were 13.5 months (95% CI 11.3 to 16.7) and 10.5 months (95% CI 8.8 to 13.7), respectively. 36 (9.5%) experienced severe treatment toxicities during follow-up. Patients with lower EQ-5D-5L utility scores (HR per 0.1 unit increase 0.84, 95% CI 0.74 to 0.95) and higher symptom burden (HR 1.11; 95% CI 1.04 to 1.19) had poorer overall survival. This was also true for those with decreased EQ-VAS and increased symptom burden between baseline and the first follow-up. Lastly, only decreased EQ-5D-5L utility scores between baseline and the first follow-up were associated with shorter time-to-progression. CONCLUSION: ePROMs may add prognostic value to clinical and tumour characteristics for overall survival in adults with advanced NSCLC receiving immunotherapy.
Description
Date
2024
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 356.33 KB
Keywords
Type
Article
Citation
Liao K, Wong DC, Gomes F, Faivre-Finn C, Moliner L, Sperrin M, et al. Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy. BMJ oncology. 2024;3(1):e000158. PubMed PMID: 39886146. Pubmed Central PMCID: PMC11203075. Epub 2025/01/31. eng.